Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase II Clinical Trial Evaluating the Efficacy and Safety of SHR1459 in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)

NCT04670770 is registered in ClinicalTrials.gov with Reistone Biopharma Company Limited as lead sponsor.

NCT NCT04670770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04670770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase II Clinical Trial Evaluating the Efficacy and Safety of SHR1459 in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)
Lead sponsor
Reistone Biopharma Company Limited
Phase
Phase 2
Overall status
Completed
Start date
January 20, 2021
Completion date
August 15, 2022
Enrollment
10 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorders